|
|
|
| Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection |
| Zhi-Feng Xi, Seogsong Jeong, Chen-Chen Wang, Hong-Jie Li, Han Guo, Jie Cai, Jia-Xin Li, Xiao-Ni Kong, Ying Tong, Qiang Xia ∗ |
Department of Liver Surgery, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai 200127, China
∗ Corresponding author.
E-mail address: xiaqiang@medmail.com.cn (Q. Xia). |
|
|
|
Abstract Background: There is no data regarding prognostic impact of interleukin (IL)-26 on outcomes of patients with hepatocellular carcinoma (HCC). The present study aimed to evaluate the prognostic impact of IL-26 on HCC patients undergoing liver resection.
Methods: From 2003 to 2008, 122 patients with HCC who received surgical curative resection were en- rolled. Patients were stratified into IL-26-upper and -lower groups according to the median expression level from immunohistochemical staining of resected specimens. Prognostic impact of IL-26 was estimated using Kaplan–Meier curves. Univariate and multivariate analyses were performed to evaluate time-dependent prognostic impact and independency of IL-26. Demographic and clinical factors that were associated with IL-26 were comprehensively identified.
Results: Prognosis of the patients with high level of IL-26 revealed to be significantly unfavorable in both cumulative recurrence-free survival ( P < 0.001) and overall survival ( P = 0.002). Upper expression of IL-26 (HR: 1.643; 95% CI: 1.021 to 2.644; P = 0.041) and microvascular invasion (HR: 3.303; 95% CI: 1.255 to 8.696; P = 0.016) were identified as significant independent prognostic factors for overall survival in the multivariable analysis.
Conclusions: IL-26 is a novel prognostic factor for HCC after resection. Evaluation of IL-26 expression may be potentially valuable in clinical therapy when planning individualized follow-up schedule and evaluat- ing candidates for prophylactic adjuvant treatment to prevent recurrence.
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
